Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 13/20 | 0.43 |
| ▸ | CCND1 | P24385 | 6/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.43 |
| ▸ | CDK2 | P24941 | 4/20 | 0.43 |
| ▸ | CDK1 | P06493 | 3/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.43 |
| ▸ | WEE1 | P30291 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 10/20 | 0.41 |
| ▸ | CSF1R | P07333 | 7/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.40 |
| ▸ | CCND3 | P30281 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.40 |
| ▸ | PAK3 | O75914 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.40 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035466 | 0.82 | CDK4 (0.43) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL15035363 | 0.82 | CDK4 (0.41) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL15041582 | 0.78 | CDK4 (0.49) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL10346808 | 0.71 | CDK4 (0.49) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL10192640 | 0.69 | CDK4 (0.59) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL25046074 | 0.67 | EGFR (0.57) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL29536837 | 0.66 | CDK4 (0.46) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL25437543 | 0.66 | CDK4 (0.46) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL10192641 | 0.66 | CDK4 (0.57) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL14575280 | 0.65 | ACVR1 (0.47) | CDK4CCND1CCNE1CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CCND1 2153/4885CCNE1 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.